- Home
- SNAL vs BNR Comparison
SNAL vs BNR Comparison
Compare SNAL & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- BNR
- Stock Information
- Founded
- SNAL 2000
- BNR 2014
- Country
- SNAL United States
- BNR China
- Employees
- SNAL N/A
- BNR N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- BNR Medical Specialities
- Sector
- SNAL Technology
- BNR Health Care
- Exchange
- SNAL Nasdaq
- BNR Nasdaq
- Market Cap
- SNAL 33.5M
- BNR 38.3M
- IPO Year
- SNAL 2022
- BNR 2020
- Fundamental
- Price
- SNAL $1.24
- BNR $9.02
- Analyst Decision
- SNAL
- BNR
- Analyst Count
- SNAL 0
- BNR 0
- Target Price
- SNAL N/A
- BNR N/A
- AVG Volume (30 Days)
- SNAL 129.5K
- BNR 24.9K
- Earning Date
- SNAL 11-12-2025
- BNR 09-08-2025
- Dividend Yield
- SNAL N/A
- BNR N/A
- EPS Growth
- SNAL N/A
- BNR N/A
- EPS
- SNAL N/A
- BNR N/A
- Revenue
- SNAL $91,041,290.00
- BNR $74,862,782.00
- Revenue This Year
- SNAL $13.87
- BNR $136.32
- Revenue Next Year
- SNAL $26.20
- BNR N/A
- P/E Ratio
- SNAL N/A
- BNR N/A
- Revenue Growth
- SNAL 24.25
- BNR 5.20
- 52 Week Low
- SNAL $0.64
- BNR $2.18
- 52 Week High
- SNAL $3.42
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- SNAL 60.80
- BNR 55.51
- Support Level
- SNAL $1.00
- BNR $8.91
- Resistance Level
- SNAL $1.38
- BNR $9.77
- Average True Range (ATR)
- SNAL 0.11
- BNR 0.54
- MACD
- SNAL 0.03
- BNR -0.04
- Stochastic Oscillator
- SNAL 67.05
- BNR 62.13
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.